-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, March 3 As of today, four vaccines have been conditionally approved for marketing in China.
Two of them are from Sinopharm Sino Biotech, and the latest two approved are the adenovirus vector vaccine of Academician Chen Wei, and the other is the latest vaccine approved for marketing by Sinopharm.
Is this vaccine different from before? In addition to inactivated vaccines and adenovirus vector vaccines, will we have vaccines with new technical routes?
Two of them are from Sinopharm Sino Biotech, and the latest two approved are the adenovirus vector vaccine of Academician Chen Wei, and the other is the latest vaccine approved for marketing by Sinopharm.
Is this vaccine different from before? In addition to inactivated vaccines and adenovirus vector vaccines, will we have vaccines with new technical routes?
Sinopharm already has a new crown vaccine,
Why do we have to produce another one?
Yang Xiaoming, Chairman of Sinopharm Group China Bio: Sinopharm established the inactivated vaccine process at the beginning of its research and development last year, and also set up the two biological products research institutes of China Biotechnology Beijing and Wuhan to develop in parallel to ensure that they can be developed and can be measured We call "double insurance" for production and listing.
Two New Coronary Inactivated Vaccines of Sinopharm Group
Is there a competitive relationship?
How should the vaccinators be selected?
Yang Xiaoming, Chairman of Sinopharm Group China Bio: Judging from the current global demand for vaccines from the new crown epidemic, the supply is still less than the demand.
In terms of the production capacity of the two production lines deployed by Sinopharm China, we strive to produce more than 1 billion doses in 2021.
From this perspective, there is a balance between supply and demand, but for the global fight against the epidemic, vaccines are far from enough.
In terms of the production capacity of the two production lines deployed by Sinopharm China, we strive to produce more than 1 billion doses in 2021.
From this perspective, there is a balance between supply and demand, but for the global fight against the epidemic, vaccines are far from enough.
Yang Xiaoming, Chairman of Sinopharm Group China Bio: From the perspective of process route, both vaccines are virus inactivated vaccines.
From the clinical data obtained in the first, second, and third clinical phases, both of them have reached the national level.
The requirements of the Supervisory Bureau.
1.
Effectiveness.
According to the protection rate obtained from the three-phase clinical data, one reached 79.
34% and the other reached 72.
51%, both of which were better than the protection rate of more than 50% required by the World Health Organization.
2.
Neutralizing antibody positive conversion rate.
Both vaccines are close to 100%, and can reach 100% in terms of critical illness protection rate.
Therefore, in terms of effectiveness and safety data, the choice of these two vaccines should be equal.
From the clinical data obtained in the first, second, and third clinical phases, both of them have reached the national level.
The requirements of the Supervisory Bureau.
1.
Effectiveness.
According to the protection rate obtained from the three-phase clinical data, one reached 79.
34% and the other reached 72.
51%, both of which were better than the protection rate of more than 50% required by the World Health Organization.
2.
Neutralizing antibody positive conversion rate.
Both vaccines are close to 100%, and can reach 100% in terms of critical illness protection rate.
Therefore, in terms of effectiveness and safety data, the choice of these two vaccines should be equal.
People who have been vaccinated against the new crown for more than half a year,
Do I need to get a third shot?
Yang Xiaoming, Chairman of Sinopharm Group China Bio: According to the immunization procedures for emergency use and marketing approval, the interval between two injections is 21 to 28 days.
The data after the two injections interval is valid for half a year.
The situation observed so far does not require half a year.
Newly strengthen the argument of the third stitch.
Only after more detailed data comes out can we know whether to strengthen it and what is the durability.
This data looks forward to more complete data in Phase III clinical trials.
The data after the two injections interval is valid for half a year.
The situation observed so far does not require half a year.
Newly strengthen the argument of the third stitch.
Only after more detailed data comes out can we know whether to strengthen it and what is the durability.
This data looks forward to more complete data in Phase III clinical trials.
Inactivated vaccine of Sinopharm Group
Is it effective against mutated new coronavirus?
Yang Xiaoming, Chairman of Sinopharm Group China Bio: Does the new crown vaccine have any effect on the mutant strain? The mutant strains in the UK and South Africa are now more representative, which poses a serious challenge to the effectiveness of the vaccine.
We used phase II and phase III clinical sera, that is, the serum after immunization with inactivated vaccines, to conduct cross-neutralization tests at home and abroad, including British and South African strains, and dozens of strains.
The results show that we are These two mutant strains in South Africa are also neutralized, and nearly a dozen strains isolated in China are also effective in neutralizing, indicating that inactivated vaccine immunization is effective against the mutant strains encountered so far.
We used phase II and phase III clinical sera, that is, the serum after immunization with inactivated vaccines, to conduct cross-neutralization tests at home and abroad, including British and South African strains, and dozens of strains.
The results show that we are These two mutant strains in South Africa are also neutralized, and nearly a dozen strains isolated in China are also effective in neutralizing, indicating that inactivated vaccine immunization is effective against the mutant strains encountered so far.
18 years of age
When can I get the new crown vaccine?
Yang Xiaoming, Chairman of Sinopharm Group China Bio: People who are susceptible to the new crown virus are all age groups, and vaccine prevention is best for all age groups.
However, when we are doing clinical phase one, two and three trials, for the sake of safety, we will do 18 to 18 59 years old, so the data for 18 to 59 years old comes out the earliest, followed by those over 60 years old, and the second is those under 17 years old and over 3 years old, divided into different ages.
Therefore, in emergency use, the approved age group is 18 to 59 years old.
The Beijing Stock Exchange, which was listed on December 30 last year, and the Wuhan Stock Exchange, which was listed on February 25 last year, the applicable age group in the listing specification is more than 18 years old, that is, over 18 years old, including all age groups over 60 years old.
For the 3 to 17-year-old age group, the clinical research data has been completed.
After finishing the data, it must be submitted to the State Food and Drug Administration as soon as possible.
However, when we are doing clinical phase one, two and three trials, for the sake of safety, we will do 18 to 18 59 years old, so the data for 18 to 59 years old comes out the earliest, followed by those over 60 years old, and the second is those under 17 years old and over 3 years old, divided into different ages.
Therefore, in emergency use, the approved age group is 18 to 59 years old.
The Beijing Stock Exchange, which was listed on December 30 last year, and the Wuhan Stock Exchange, which was listed on February 25 last year, the applicable age group in the listing specification is more than 18 years old, that is, over 18 years old, including all age groups over 60 years old.
For the 3 to 17-year-old age group, the clinical research data has been completed.
After finishing the data, it must be submitted to the State Food and Drug Administration as soon as possible.
Medical Network News, March 3 As of today, four vaccines have been conditionally approved for marketing in China.
Two of them are from Sinopharm Sino Biotech, and the latest two approved are the adenovirus vector vaccine of Academician Chen Wei, and the other is the latest vaccine approved for marketing by Sinopharm.
Is this vaccine different from before? In addition to inactivated vaccines and adenovirus vector vaccines, will we have vaccines with new technical routes?
Two of them are from Sinopharm Sino Biotech, and the latest two approved are the adenovirus vector vaccine of Academician Chen Wei, and the other is the latest vaccine approved for marketing by Sinopharm.
Is this vaccine different from before? In addition to inactivated vaccines and adenovirus vector vaccines, will we have vaccines with new technical routes?
Sinopharm already has a new crown vaccine,
Why do we have to produce another one?
Yang Xiaoming, Chairman of Sinopharm Group China Bio: Sinopharm established the inactivated vaccine process at the beginning of its research and development last year, and also set up the two biological products research institutes of China Biotechnology Beijing and Wuhan to develop in parallel to ensure that they can be developed and can be measured We call "double insurance" for production and listing.
Two New Coronary Inactivated Vaccines of Sinopharm Group
Is there a competitive relationship?
How should the vaccinators be selected?
Yang Xiaoming, Chairman of Sinopharm Group China Bio: Judging from the current global demand for vaccines from the new crown epidemic, the supply is still less than the demand.
In terms of the production capacity of the two production lines deployed by Sinopharm China, we strive to produce more than 1 billion doses in 2021.
From this perspective, there is a balance between supply and demand, but for the global fight against the epidemic, vaccines are far from enough.
In terms of the production capacity of the two production lines deployed by Sinopharm China, we strive to produce more than 1 billion doses in 2021.
From this perspective, there is a balance between supply and demand, but for the global fight against the epidemic, vaccines are far from enough.
Yang Xiaoming, Chairman of Sinopharm Group China Bio: From the perspective of process route, both vaccines are virus inactivated vaccines.
From the clinical data obtained in the first, second, and third clinical phases, both of them have reached the national level.
The requirements of the Supervisory Bureau.
1.
Effectiveness.
According to the protection rate obtained from the three-phase clinical data, one reached 79.
34% and the other reached 72.
51%, both of which were better than the protection rate of more than 50% required by the World Health Organization.
2.
Neutralizing antibody positive conversion rate.
Both vaccines are close to 100%, and can reach 100% in terms of critical illness protection rate.
Therefore, in terms of effectiveness and safety data, the choice of these two vaccines should be equal.
From the clinical data obtained in the first, second, and third clinical phases, both of them have reached the national level.
The requirements of the Supervisory Bureau.
1.
Effectiveness.
According to the protection rate obtained from the three-phase clinical data, one reached 79.
34% and the other reached 72.
51%, both of which were better than the protection rate of more than 50% required by the World Health Organization.
2.
Neutralizing antibody positive conversion rate.
Both vaccines are close to 100%, and can reach 100% in terms of critical illness protection rate.
Therefore, in terms of effectiveness and safety data, the choice of these two vaccines should be equal.
People who have been vaccinated against the new crown for more than half a year,
Do I need to get a third shot?
Yang Xiaoming, Chairman of Sinopharm Group China Bio: According to the immunization procedures for emergency use and marketing approval, the interval between two injections is 21 to 28 days.
The data after the two injections interval is valid for half a year.
The situation observed so far does not require half a year.
Newly strengthen the argument of the third stitch.
Only after more detailed data comes out can we know whether to strengthen it and what is the durability.
This data looks forward to more complete data in Phase III clinical trials.
The data after the two injections interval is valid for half a year.
The situation observed so far does not require half a year.
Newly strengthen the argument of the third stitch.
Only after more detailed data comes out can we know whether to strengthen it and what is the durability.
This data looks forward to more complete data in Phase III clinical trials.
Inactivated vaccine of Sinopharm Group
Is it effective against mutated new coronavirus?
Yang Xiaoming, Chairman of Sinopharm Group China Bio: Does the new crown vaccine have any effect on the mutant strain? The mutant strains in the UK and South Africa are now more representative, which poses a serious challenge to the effectiveness of the vaccine.
We used phase II and phase III clinical sera, that is, the serum after immunization with inactivated vaccines, to conduct cross-neutralization tests at home and abroad, including British and South African strains, and dozens of strains.
The results show that we are These two mutant strains in South Africa are also neutralized, and nearly a dozen strains isolated in China are also effective in neutralizing, indicating that inactivated vaccine immunization is effective against the mutant strains encountered so far.
We used phase II and phase III clinical sera, that is, the serum after immunization with inactivated vaccines, to conduct cross-neutralization tests at home and abroad, including British and South African strains, and dozens of strains.
The results show that we are These two mutant strains in South Africa are also neutralized, and nearly a dozen strains isolated in China are also effective in neutralizing, indicating that inactivated vaccine immunization is effective against the mutant strains encountered so far.
18 years of age
When can I get the new crown vaccine?
Yang Xiaoming, Chairman of Sinopharm Group China Bio: People who are susceptible to the new crown virus are all age groups, and vaccine prevention is best for all age groups.
However, when we are doing clinical phase one, two and three trials, for the sake of safety, we will do 18 to 18 59 years old, so the data for 18 to 59 years old comes out the earliest, followed by those over 60 years old, and the second is those under 17 years old and over 3 years old, divided into different ages.
Therefore, in emergency use, the approved age group is 18 to 59 years old.
The Beijing Stock Exchange, which was listed on December 30 last year, and the Wuhan Stock Exchange, which was listed on February 25 last year, the applicable age group in the listing specification is more than 18 years old, that is, over 18 years old, including all age groups over 60 years old.
For the 3 to 17-year-old age group, the clinical research data has been completed.
After finishing the data, it must be submitted to the State Food and Drug Administration as soon as possible.
However, when we are doing clinical phase one, two and three trials, for the sake of safety, we will do 18 to 18 59 years old, so the data for 18 to 59 years old comes out the earliest, followed by those over 60 years old, and the second is those under 17 years old and over 3 years old, divided into different ages.
Therefore, in emergency use, the approved age group is 18 to 59 years old.
The Beijing Stock Exchange, which was listed on December 30 last year, and the Wuhan Stock Exchange, which was listed on February 25 last year, the applicable age group in the listing specification is more than 18 years old, that is, over 18 years old, including all age groups over 60 years old.
For the 3 to 17-year-old age group, the clinical research data has been completed.
After finishing the data, it must be submitted to the State Food and Drug Administration as soon as possible.
Medical Network News, March 3 As of today, four vaccines have been conditionally approved for marketing in China.
Two of them are from Sinopharm Sino Biotech, and the latest two approved are the adenovirus vector vaccine of Academician Chen Wei, and the other is the latest vaccine approved for marketing by Sinopharm.
Is this vaccine different from before? In addition to inactivated vaccines and adenovirus vector vaccines, will we have vaccines with new technical routes?
Two of them are from Sinopharm Sino Biotech, and the latest two approved are the adenovirus vector vaccine of Academician Chen Wei, and the other is the latest vaccine approved for marketing by Sinopharm.
Is this vaccine different from before? In addition to inactivated vaccines and adenovirus vector vaccines, will we have vaccines with new technical routes?
Sinopharm already has a new crown vaccine,
Sinopharm already has a new crown vaccine, Why do we have to produce another one?
Why do we have to produce another one? Yang Xiaoming, Chairman of Sinopharm Group China Bio: Sinopharm established the inactivated vaccine process at the beginning of its research and development last year, and also set up the two biological products research institutes of China Biotechnology Beijing and Wuhan to develop in parallel to ensure that they can be developed and can be measured We call "double insurance" for production and listing.
Two New Coronary Inactivated Vaccines of Sinopharm Group
Two New Coronary Inactivated Vaccines of Sinopharm Group Is there a competitive relationship?
Is there a competitive relationship? How should the vaccinators be selected?
How should the vaccinators be selected? Yang Xiaoming, Chairman of Sinopharm Group China Bio: Judging from the current global demand for vaccines from the new crown epidemic, the supply is still less than the demand.
In terms of the production capacity of the two production lines deployed by Sinopharm China, we strive to produce more than 1 billion doses in 2021.
From this perspective, there is a balance between supply and demand, but for the global fight against the epidemic, vaccines are far from enough.
In terms of the production capacity of the two production lines deployed by Sinopharm China, we strive to produce more than 1 billion doses in 2021.
From this perspective, there is a balance between supply and demand, but for the global fight against the epidemic, vaccines are far from enough.
Yang Xiaoming, Chairman of Sinopharm Group China Bio: From the perspective of process route, both vaccines are virus inactivated vaccines.
From the clinical data obtained in the first, second, and third clinical phases, both of them have reached the national level.
The requirements of the Supervisory Bureau.
1.
Effectiveness.
According to the protection rate obtained from the three-phase clinical data, one reached 79.
34% and the other reached 72.
51%, both of which were better than the protection rate of more than 50% required by the World Health Organization.
2.
Neutralizing antibody positive conversion rate.
Both vaccines are close to 100%, and can reach 100% in terms of critical illness protection rate.
Therefore, in terms of effectiveness and safety data, the choice of these two vaccines should be equal.
From the clinical data obtained in the first, second, and third clinical phases, both of them have reached the national level.
The requirements of the Supervisory Bureau.
1.
Effectiveness.
According to the protection rate obtained from the three-phase clinical data, one reached 79.
34% and the other reached 72.
51%, both of which were better than the protection rate of more than 50% required by the World Health Organization.
2.
Neutralizing antibody positive conversion rate.
Both vaccines are close to 100%, and can reach 100% in terms of critical illness protection rate.
Therefore, in terms of effectiveness and safety data, the choice of these two vaccines should be equal.
People who have been vaccinated against the new crown for more than half a year,
People who have been vaccinated against the new crown for more than half a year, Do I need to get a third shot?
Do I need to get a third shot? Yang Xiaoming, Chairman of Sinopharm Group China Bio: According to the immunization procedures for emergency use and marketing approval, the interval between two injections is 21 to 28 days.
The data after the two injections interval is valid for half a year.
The situation observed so far does not require half a year.
Newly strengthen the argument of the third stitch.
Only after more detailed data comes out can we know whether to strengthen it and what is the durability.
This data looks forward to more complete data in Phase III clinical trials.
The data after the two injections interval is valid for half a year.
The situation observed so far does not require half a year.
Newly strengthen the argument of the third stitch.
Only after more detailed data comes out can we know whether to strengthen it and what is the durability.
This data looks forward to more complete data in Phase III clinical trials.
Inactivated vaccine of Sinopharm Group
Inactivated vaccine of Sinopharm Group Is it effective against mutated new coronavirus?
Is it effective against mutated new coronavirus? Yang Xiaoming, Chairman of Sinopharm Group China Bio: Does the new crown vaccine have any effect on the mutant strain? The mutant strains in the UK and South Africa are now more representative, which poses a serious challenge to the effectiveness of the vaccine.
We used phase II and phase III clinical sera, that is, the serum after immunization with inactivated vaccines, to conduct cross-neutralization tests at home and abroad, including British and South African strains, and dozens of strains.
The results show that we are These two mutant strains in South Africa are also neutralized, and nearly a dozen strains isolated in China are also effective in neutralizing, indicating that inactivated vaccine immunization is effective against the mutant strains encountered so far.
We used phase II and phase III clinical sera, that is, the serum after immunization with inactivated vaccines, to conduct cross-neutralization tests at home and abroad, including British and South African strains, and dozens of strains.
The results show that we are These two mutant strains in South Africa are also neutralized, and nearly a dozen strains isolated in China are also effective in neutralizing, indicating that inactivated vaccine immunization is effective against the mutant strains encountered so far.
18 years of age
18 years of age When can I get the new crown vaccine?
When can I get the new crown vaccine? Yang Xiaoming, Chairman of Sinopharm Group China Bio: People who are susceptible to the new crown virus are all age groups, and vaccine prevention is best for all age groups.
However, when we are doing clinical phase one, two and three trials, for the sake of safety, we will do 18 to 18 59 years old, so the data for 18 to 59 years old comes out the earliest, followed by those over 60 years old, and the second is those under 17 years old and over 3 years old, divided into different ages.
Therefore, in emergency use, the approved age group is 18 to 59 years old.
The Beijing Stock Exchange, which was listed on December 30 last year, and the Wuhan Stock Exchange, which was listed on February 25 last year, the applicable age group in the listing specification is more than 18 years old, that is, over 18 years old, including all age groups over 60 years old.
For the 3 to 17-year-old age group, the clinical research data has been completed.
After finishing the data, it must be submitted to the State Food and Drug Administration as soon as possible.
However, when we are doing clinical phase one, two and three trials, for the sake of safety, we will do 18 to 18 59 years old, so the data for 18 to 59 years old comes out the earliest, followed by those over 60 years old, and the second is those under 17 years old and over 3 years old, divided into different ages.
Therefore, in emergency use, the approved age group is 18 to 59 years old.
The Beijing Stock Exchange, which was listed on December 30 last year, and the Wuhan Stock Exchange, which was listed on February 25 last year, the applicable age group in the listing specification is more than 18 years old, that is, over 18 years old, including all age groups over 60 years old.
For the 3 to 17-year-old age group, the clinical research data has been completed.
After finishing the data, it must be submitted to the State Food and Drug Administration as soon as possible.
